Partnerships and collaborations enable our ability to accelerate the global investigation of novel combination treatments that address major unmet needs and have the potential to improve outcomes for people with cancer around the world.
Strategic partners to advance global development and commercialization activities:
- Gilead and Arcus have a 10-year all-in partnership that included a significant capital investment and equity stake by Gilead into Arcus. Gilead holds co-development and co-commercialization rights to zimberelimab (anti-PD1 antibody) and an option to license current and future molecules.
- Taiho has exercised option rights in Japan and other countries in Asia (excluding China) for the majority of Arcus’ clinical portfolio ̶ including domvanalimab, zimberelimab, etrumadenant, and AB308.
Clinical collaborations to explore novel combinations
Arcus is interested in clinical collaborations that evaluate novel combinations of Arcus molecules with other companies’ medicines or diagnostics to expand our understanding of important pathways and facilitate global access to expedite development and commercialization.
- AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent